Thermo Fisher Scientific has been granted 510(k) clearance from the FDA for its SeCore CDx HLA A Sequencing System to be used as a companion diagnostic with TECELRA, a T-cell receptor therapy developed by Adaptimmune for treating synovial sarcoma in adults.
The SeCore CDx HLA A Sequencing System is a diagnostic device beneficial for patients needing T-cell receptor therapies, performing high-resolution HLA typing, crucial for pinpointing suitable candidates for therapies such as TECELRA. It is primarily used for determining the compatibility of HLA proteins that trigger an immune response.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.